Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

Study identifier:NIS-OTH-IRE-2009/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand

Medical condition

lung cancer

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

104

Study type

Observational

Age

N/A

Date

Study Start Date: 01 Oct 2009

Primary Completion Date: 01 Aug 2010

Study Completion Date: 01 Aug 2010

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Bangkok, Thailand

Arms	Assigned Interventions

Documents available

CSR-NIS-OTH-IRE-2009-1.pdf
Download
CSR-NIS-OTH-IRE-2009-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Thailand Study Information

+66 8 9201 4908

chantana.timsri@astrazeneca.com

Investigators

Principal Investigator

Virote Sriuranpong

Chulalongkorn Hospital, Bangkok, Thailand